Stockreport

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform [Yahoo! Finance...

Dyadic International, Inc.  (DYAI) 
NASDAQ:AMEX Investor Relations: dyadic.com
PDF the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for [Read more]